These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16409833)

  • 61. Prostate carcinoma: clarification through clinical insight and molecular diagnostics.
    Meyers FJ; DeVere White RW
    West J Med; 1998 Jun; 168(6):525. PubMed ID: 9655997
    [No Abstract]   [Full Text] [Related]  

  • 62. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
    Perrin P
    Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
    [No Abstract]   [Full Text] [Related]  

  • 63. Early detection of prostate cancer.
    Taneja SS
    Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
    [No Abstract]   [Full Text] [Related]  

  • 64. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prostate specific antigen screening and active surveillance in the elderly.
    Konety BR
    J Urol; 2009 Apr; 181(4):1534-5. PubMed ID: 19230925
    [No Abstract]   [Full Text] [Related]  

  • 66. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 67. The challenges of prostate cancer detection. Interview by Carren Bersch.
    Tomaszewski JE; Zarbo RJ
    MLO Med Lab Obs; 2004 Feb; 36(2):26, 30-1. PubMed ID: 15002150
    [No Abstract]   [Full Text] [Related]  

  • 68. Screening for prostate cancer in 2007: the PSA era and its challenges are not over.
    Shariat SF; Karakiewicz PI
    Eur Urol; 2008 Mar; 53(3):457-60. PubMed ID: 18079050
    [No Abstract]   [Full Text] [Related]  

  • 69. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management].
    Malmström PU
    Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565
    [No Abstract]   [Full Text] [Related]  

  • 70. Prostate cancer screening with PSA: "Aequanimitas".
    Sadi MV
    Int Braz J Urol; 2013; 39(4):447-53. PubMed ID: 24054394
    [No Abstract]   [Full Text] [Related]  

  • 71. Biomarkers for prostate cancer detection.
    Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
    J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Prostate specific antigen adjusted for the transition zone volume].
    Maeda H; Aoki Y; Arai Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():108-11. PubMed ID: 11022695
    [No Abstract]   [Full Text] [Related]  

  • 73. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary].
    Damber JE
    Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209
    [No Abstract]   [Full Text] [Related]  

  • 74. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 75. [Screening for prostate cancer--what does the evidence show?].
    Borre M; Iversen P
    Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is the PSA test useless?
    Kirby R; Moul JW
    Prostate Cancer Prostatic Dis; 2004; 7(4):271-2. PubMed ID: 15592438
    [No Abstract]   [Full Text] [Related]  

  • 77. No one dies from prostate cancer?
    Chau D
    Arch Intern Med; 2006 Jul; 166(14):1525; author reply 1526. PubMed ID: 16864764
    [No Abstract]   [Full Text] [Related]  

  • 78. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
    Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Authorities in USA don't recommend screening for prostate cancer].
    Bratt O
    Lakartidningen; 2011 Nov 16-22; 108(46):2362. PubMed ID: 22468374
    [No Abstract]   [Full Text] [Related]  

  • 80. [Systematic PSA screening has been tried in Region Skåne. Balanced information gives chance for equal treatment according to a pilot project].
    Bratt O; Lundgren R; Ahlgren G
    Lakartidningen; 2012 Sep 12-18; 109(37):1610-2. PubMed ID: 23077769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.